Evidence map›Paper›PMID 32658963›Full record

ArticleRheumatology (Oxford, England)2021

Performance of the 2019 ACR/EULAR classification criteria for IgG4-related disease and clinical phenotypes in a Spanish multicentre registry (REERIGG4).

Andreu Fernández-Codina, Blanca Pinilla, Iago Pinal-Fernández, Iago Carballo, Carlos Feijoo-Massó, María Toledano-Macías, Borja de Miguel-Campo, Eva Fonseca-Aizpuru, Luis Sáez-Comet, Miguel López-Dupla and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andreu Fernández-CodinaInternal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Blanca PinillaInternal Medicine Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Iago Pinal-FernándezMuscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA.
Iago CarballoInternal Medicine Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela.
Carlos Feijoo-MassóInternal Medicine Department, Consorci Sanitari Parc Taulí, Sabadell.
María Toledano-MacíasInternal Medicine Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Borja de Miguel-CampoInternal Medicine Department, Hospital 12 de octubre, Madrid.
Eva Fonseca-AizpuruInternal Medicine Department, Hospital de Cabueñes, Gijón.
Luis Sáez-CometInternal Medicine Department, Hospital Miguel Servet, Zaragoza.
Miguel López-DuplaInternal Medicine Department, Hospital Joan XXXIII, Tarragona.
José Hernández-RodríguezInternal Medicine Department, Hospital Clínic i Provincial, Barcelona, Spain.
Fernando Martínez-ValleInternal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSeveral IgG4-related disease (IgG4-RD) phenotypes have been proposed and the first set of classification criteria have been recently created. Our objectives were to assess the phenotype distribution and the performance of the classification criteria in Spanish patients as genetic and geographical differences may exist.

methodsWe performed a cross-sectional multicentre study (Registro Español de Enfermedad Relacionada con la IgG4, REERIGG4) with nine participating centres from Spain. Patients were recruited from November 2013 to December 2018. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria (AECC) were used.

resultsWe included 105 patients; 88% had Caucasian ethnicity. On diagnosis, 86% met the international pathology consensus while 92% met the Japanese comprehensive criteria. The phenotype distribution was head and neck 25%, Mikulicz and systemic (MS) 20%, pancreato-hepato-biliary (PHB) 13%, retroperitoneal and aorta (RA) 26%. Sixteen per cent had an undefined phenotype. Seventy-seven per cent of the cases met the AECC. From the 24 patients not meeting the AECC, 33% met exclusion criteria, and 67% did not get a score ≥20 points. Incomplete pathology reports were associated to failure to meet the AECC.

conclusionsThe PHB phenotype was rare among Spanish IgG4-RD patients. The MS phenotype was less frequent and the RA phenotype was more prevalent than in other, Asian patient series. An undefined phenotype should be considered as some patients do not fall into any of the categories. Three quarters of the cases met the 2019 AECC. Incomplete pathology reports were the leading causes of failure to meet the criteria.

Indexed as

Immunoglobulin GPhenotypeRegistriesAge FactorsCross-Sectional StudiesDatabases, FactualFemaleHumansImmunoglobulin G4-Related DiseaseMaleMiddle AgedProhibitinsSex FactorsSpainWhite PeopleImmunoglobulin GPHB protein, humanProhibitinsclassification criteriaIgG4-related diseasephenotypes

Identifiers

PMID32658963
PMCPMC8453617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.